Johnson & Johnson

Joaquin Duato as Chairman and CEO holds ultimate authority over capital allocation, supported by CFO Joseph Wolk. The board of directors reviews major acquisitions and strategic restructurings, such as the $16.6 billion Abiomed transaction in 2022. Individual segment heads for pharmaceuticals and medtech propose and advocate for M&A targets within their therapeutic areas, but final approval rests with the C-suite and board.

Deal flow is sourced through a combination of its venture arm, Johnson & Johnson Innovation — JJDC, which takes early-stage equity stakes in biotech and healthtech startups globally, and the business development teams embedded in each therapeutic franchise. The firm operates four JLABS incubators in San Diego, New York, Toronto, and Belgium, giving it early visibility into novel science before companies reach commercial-stage investors. Longstanding relationships with academic medical centers and venture capital firms in Boston, San Francisco, and Cambridge UK provide additional proprietary access.

Johnson & Johnson primarily executes direct acquisitions and licensing deals, not blind-pool fund commitments. Through JJDC, it makes direct equity investments in startups but does not operate as a limited partner in external venture capital funds. The firm's preferred structure is a full buyout or a structured option-to-acquire deal with development milestones, as seen in the Momenta Pharmaceuticals and Abiomed transactions.

JJDC targets seed through Series C rounds for platform technologies in immunology, oncology, gene therapy, and surgical robotics. The parent company's M&A group focuses on late-stage private and publicly traded companies with FDA-approved products or those in Phase 3 trials. The Abiomed acquisition in 2022 exemplifies the mature, commercial-stage preference for larger transactions, while earlier investments in companies like Verb Surgical (in partnership with Alphabet) show a willingness to seed entirely new platforms.

The August 2023 spinoff of Kenvue removed all consumer health brands — including Tylenol, Neutrogena, and Band-Aid — from Johnson & Johnson's balance sheet. This leaves the parent company solely focused on higher-margin pharmaceuticals and medical devices. The move is structurally significant: Johnson & Johnson now competes more directly with pure-play pharma firms like Pfizer and medtech companies like Medtronic, without the conglomerate discount that diversified healthcare firms typically carry.

No. Johnson & Johnson is a widely held public company with no controlling family shareholder. The Johnson family's influence waned generations ago, and ownership is now institutional — Vanguard, BlackRock, and State Street are the largest shareholders. There is no single-family office arm, and executive compensation is in standard public-company equity and cash, not a family wealth management arrangement.

Oncology and immunology are the two highest-priority areas for pharmaceutical investment, with multiple myeloma and solid tumors receiving heavy R&D spending and deal activity. In medical devices, cardiovascular interventions, orthopedics, and surgical robotics dominate capital allocation — the Abiomed and Auris Health acquisitions are representative. The firm has explicitly deprioritized consumer health entirely through the Kenvue separation and has exited certain antibiotics and respiratory drug categories through portfolio rationalizations over the past decade (per the firm's 2023 annual report).